193. Prader-Willi syndrome Clinical trials / Disease details
Clinical trials : 113 / Drugs : 111 - (DrugBank : 26) / Drug target genes : 48 - Drug target pathways : 102
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05504395 (ClinicalTrials.gov) | November 14, 2022 | 4/8/2022 | A Pharmacokinetic and Safety Study of CSTI-500 in Subjects With Prader-Willi Syndrome | A Phase 1, Single Center, Open Label, Single Dose, Pharmacokinetic and Safety Study of CSTI-500 in Subjects With Prader-Willi Syndrome | Prader-Willi Syndrome | Drug: CSTI-500 | ConSynance Therapeutics | NULL | Recruiting | 13 Years | 50 Years | All | 14 | Phase 1 | United States |